BiotechTube
Atengen

Atengen

Cambridge, United States· Est.
atengen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Atengen is pioneering a groundbreaking anti-angiogenic strategy that targets a specific receptor on tumor blood vessels to treat solid tumors. Founded in 2018 and based in Cambridge, MA, the company leverages a novel therapeutic target to develop both small molecule and antibody therapies intended to starve tumors by destroying their blood supply. This approach aims to be broadly applicable across many cancer types while minimizing resistance and off-target effects. The company is in the pre-clinical stage, supported by a world-class Scientific Advisory Board with deep expertise in oncology, angiogenesis, and drug development.

Oncology

Technology Platform

Platform focused on a novel receptor target specifically expressed on tumor blood vessels. Utilizes discovery technologies to identify small molecule and antibody drug candidates that induce cytotoxicity in tumor vasculature for a pan-cancer, tissue-agnostic approach.

Opportunities

The significant unmet need in treating resistant solid tumors creates a large addressable market.
A successful tissue-agnostic, anti-vascular therapy could benefit a broad patient population across multiple cancer types, potentially enabling faster regulatory pathways.
The novel mechanism may overcome limitations of previous angiogenesis inhibitors, offering a differentiated product profile.

Risk Factors

High scientific risk associated with validating a novel biological target and demonstrating clinical safety, as damaging normal vasculature could be catastrophic.
Financial risk is inherent as a private, early-stage company with undisclosed funding.
Competition from other next-generation vascular-targeting and pan-cancer modalities is substantial.

Competitive Landscape

Atengen competes in the anti-angiogenesis and vascular-disrupting agent space, which includes established VEGF-targeting drugs (e.g., bevacizumab) and newer approaches. It also competes indirectly with other tissue-agnostic therapies (e.g., immunotherapies for MSI-H tumors). Key differentiators are the claimed specificity of its receptor for tumor vasculature and its aim to directly kill vessels rather than merely inhibit growth.

More companies in Oncology (General) →More companies in United States →